© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to June
mTORC1-selective bi-steric mTOR inhibitor
QW IP activity in xeno., 5552 in Ph. I for cancer
from linking of ÒrapalogÓ + mTOR inh. + opt
Nature Chemical Biology
Revolution Medicines, Redwood City, US
3. The Revolution Medicines selective mTORC1 complex inhibitor, RMC-4529, is a Òbi-stericÓ inhibitor that has a rapamycin-derived, FKBP12-recruiting allosteric mTOR inhibitor covalently linked to an active-site (orthosteric) inhibitor of…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.